Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Polycystic Ovary Syndrome 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Recurrence 1Multiple Myeloma 1Leukemia, Myeloid, Chronic-Phase 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 11Rituximab 10Gemcitabine 9Paclitaxel 7Lenalidomide 7Decitabine 7Cytarabine 7Bendamustine Hydrochloride 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Carboplatin 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Antilymphocyte Serum 4tislelizumab 3pomalidomide 3liposomal doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Recurrence × Pioglitazone × Clear all
NCT01010243 2012-05-30

MM03

University of Regensburg

Phase 1/2 Unknown
54 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡